Assessment of Combined Growth Hormone and Gonadotropin-Releasing Hormone Analogue Treatment in Children with Silver-Russell Syndrome
Authors' conclusion
Combined treatment with rhGH and GnRHa for children with SRS resulted in AH within standard references for more than half of our cohort and appears to be safe in this population.
Study context
- Population
- Children with molecularly confirmed Silver-Russell syndrome, aged 14 years and over, treated with recombinant human growth hormone (rhGH) and gonadotropin-releasing hormone analogue (GnRHa), at a reference centre for rare disorders in Franceanalysed
- Participants
- 39 children
- Exposure
- Combined rhGH and GnRHa
- Girlsn = 17
- Boysn = 22
- Outcome
- Adult height (AH) and tolerance
Methodological detailssingle reference centre
- Single reference centre
Main finding
As reported in the abstract
AH SDS
Girls
−2.1
IQR −2.4–-1.5 · standard deviation score (SDS)
Boys
−1.4
IQR −1.9–-1.2 · SDS
- Adult height (AH) reached
- 30 patients (76.9%)
- Median AH SDS (all)
- −1.8 (−2.4 to −1.1)
Observational data: associations, not effects.
Further findings
Pubertal height gain
Age at treatment start
- Median age at start of rhGH (years)
- 3.9 (2.8-5.0)
- Median age at start of GnRHa (years)
- 10.0 (9.3-11.0)
Safety
- Tolerance was good, few drug-related adverse effects
Original publication
Assessment of Combined Growth Hormone and Gonadotropin-Releasing Hormone Analogue Treatment in Children with Silver-Russell Syndrome. Horm Res Paediatr. Published 16 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →